×
Use Able AI chat for product recommendations

Validation Data Gallery

  • <b>Human PBMCs co-stained with anti-CD4 recombinant VHH and anti-CD3 UCHT1 in Flow Cytometry</b><br/> 1x10^6 human PBMCs were surface co-stained in 100 µL with 0.25 µg anti-CD4 recombinant VHH, FITC Plus (MG-1229FITC, Clone: CTK0242) or 0.25 µg recombinant VHH Isotype Control, FITC Plus (Clone: CTK0201), mixed with 5 µL Anti-Human CD3, CoraLite® Plus 647 (CL647-65151, Clone: UCHT1). Fc-receptors were blocked. Viability Dye (PD00002) was used. Cells were not fixed. Viable lymphocytes were gated.

    Human PBMCs co-stained with anti-CD4 recombinant VHH and anti-CD3 UCHT1 in Flow Cytometry
    1x10^6 human PBMCs were surface co-stained in 100 µL with 0.25 µg anti-CD4 recombinant VHH, FITC Plus (MG-1229FITC, Clone: CTK0242) or 0.25 µg recombinant VHH Isotype Control, FITC Plus (Clone: CTK0201), mixed with 5 µL Anti-Human CD3, CoraLite® Plus 647 (CL647-65151, Clone: UCHT1). Fc-receptors were blocked. Viability Dye (PD00002) was used. Cells were not fixed. Viable lymphocytes were gated.

  • <b>Human PBMCs stained with anti-CD4 recombinant VHH in Flow Cytometry</b><br/> 1x10^6 human PBMCs were surface stained in 100 µL with 0.25 µg anti-CD4 recombinant VHH, FITC Plus (MG-1229FITC, Clone: CTK0242) (red), or 0.25 µg recombinant VHH Isotype Control, FITC Plus (Clone: CTK0201, blue). Fc-receptors were blocked. Viability Dye (PD00002) was used. Cells were not fixed. Viable lymphocytes were gated.

    Human PBMCs stained with anti-CD4 recombinant VHH in Flow Cytometry
    1x10^6 human PBMCs were surface stained in 100 µL with 0.25 µg anti-CD4 recombinant VHH, FITC Plus (MG-1229FITC, Clone: CTK0242) (red), or 0.25 µg recombinant VHH Isotype Control, FITC Plus (Clone: CTK0201, blue). Fc-receptors were blocked. Viability Dye (PD00002) was used. Cells were not fixed. Viable lymphocytes were gated.

  • <b>Human PBMCs competitively co-stained with anti-CD4 recombinant VHH and anti-CD4 RPA-T4 in Flow Cytometry</b><br/> 1x10^6 human PBMCs were surface co-stained in 100 µL with 0.25 µg anti-CD4 recombinant VHH, FITC Plus (MG-1229FITC, Clone: CTK0242) mixed with 5 µL Anti-Human CD4, CoraLite® Plus 647 (CL647-65143, Clone: RPA-T4) (middle). As controls 0.25 µg VHH were co-stained with 0.25 µg Mouse IgG1, κ Isotype Control, CoraLite® Plus 647 (CL647-65124, Clone: MOPC-21) (left), and 5 µL RPA-T4 were co-stained with 0.25 µg recombinant VHH Isotype Control, FITC Plus (Clone: CTK0201, right). Fc-receptors were blocked. Viability Dye (PD00002) was used. Cells were not fixed. Viable lymphocytes were gated. Anti-Human CD4 recombinant VHH clone CTK0242 effectively co-stains the same CD4+ population as the conventional Anti-Human CD4 Mouse IgG1 clone RPA-T4.

    Human PBMCs competitively co-stained with anti-CD4 recombinant VHH and anti-CD4 RPA-T4 in Flow Cytometry
    1x10^6 human PBMCs were surface co-stained in 100 µL with 0.25 µg anti-CD4 recombinant VHH, FITC Plus (MG-1229FITC, Clone: CTK0242) mixed with 5 µL Anti-Human CD4, CoraLite® Plus 647 (CL647-65143, Clone: RPA-T4) (middle). As controls 0.25 µg VHH were co-stained with 0.25 µg Mouse IgG1, κ Isotype Control, CoraLite® Plus 647 (CL647-65124, Clone: MOPC-21) (left), and 5 µL RPA-T4 were co-stained with 0.25 µg recombinant VHH Isotype Control, FITC Plus (Clone: CTK0201, right). Fc-receptors were blocked. Viability Dye (PD00002) was used. Cells were not fixed. Viable lymphocytes were gated. Anti-Human CD4 recombinant VHH clone CTK0242 effectively co-stains the same CD4+ population as the conventional Anti-Human CD4 Mouse IgG1 clone RPA-T4.

ChromoTek anti-CD4 recombinant VHH, FITC Plus

The small size of VHHs (~15 kDa) enables access to epitopes that may be sterically inaccessible to full size IgGs. Their reduced steric hindrance also facilitates simultaneous staining of multiple targets, making them particularly useful for applications like Nano-Flow. MG-1229FITC is a recombinant FITC conjugated anti CD4 Nanobody (VHH) that targets CD4 (human).
Cat No. MG-1229FITC

Review Product

Host/Type

Alpaca VHH

Reactivity

Human

Applications

FC

Conjugate

FITC Plus

Synonyms

T4 VHH, CD4 VHH

Formats:  FITC Plus
Size: 

-/ -

Freight/Packing: -

Concentration: 0.5 mg/ml

Quantity

- +

Request bulk or custom quote

Please visit your regions distributor:

Product Information

The small size of VHHs (~15 kDa) enables access to epitopes that may be sterically inaccessible to full size IgGs. Their reduced steric hindrance also facilitates simultaneous staining of multiple targets, making them particularly useful for applications like Nano-Flow. MG-1229FITC is a recombinant FITC conjugated anti CD4 Nanobody (VHH) that targets CD4 (human).

ApplicationsFC
ReactivityHuman
ConjugateFITC Plus
TypeNanobody
ClassRecombinant
HostAlpaca
Affinity17 nM
CloneCTK0242
Immunogen26-396 aa
Molecular Weight14.8 kDa
FormLiquid
Excitation/Emission Maxima Wavelengths500 nm / 520 nm
RRID/
Storage Buffer10 mM HEPES pH 7.0, 500 mM NaCl, 5 mM EDTA, 0.09% sodium azide
Storage ConditionStore at -20°C
Shippingblue ice
Sizes150 µl
Amount per test (Flow Cytometry)0.5 µl per test
Total number of tests300 tests
BackgroundCD4 is a 55-kDa transmembrane glycoprotein expressed on T helper cells, majority of thymocytes, monocytes, macrophages, and dendritic cells (PMID: 9304802; 12213222). CD4 is an accessory protein for MHC class-II antigen/T-cell receptor interaction. It plays an important role in T helper cell development and activation (PMID: 9539765; 3112582). CD4 serves as a receptor for the human immunodeficiency virus (HIV) (PMID: 9304802).
||
New chat

Able™

正在加载，请稍候...